Zhejiang Benli Technology Co., Ltd. announced that it has received approval from the Zhejiang Medical Products Administration to adjust the production scope of its norfloxacin active pharmaceutical ingredient from 'registration application use only' to formal production. The production site, production line, and workshop remain unchanged, and a new drug GMP compliance inspection number has been added. The company stated that this change will not have a significant impact on its performance in the short term, but future sales are subject to uncertainty due to policy and market environment factors.
Zhejiang Benli Technology Co. Ltd.Zhejiang Medical Products Administration approved Benli to move norfloxacin API from registration-only use to formal production, adding a GMP compliance number.
